Literature DB >> 35293579

Programmable manipulation of oligonucleotide-albumin interaction for elongated circulation time.

Cai Yang1,2, Haitao Zhao1, Yang Sun1, Cheng Wang1, Xinyao Geng1, Ruowen Wang1, Lumin Tang1, Da Han1, Jianjun Liu1, Weihong Tan1,2.   

Abstract

Oligonucleotide (ON) therapeutics are emerging as a new generation of medicine with tremendous potential, but their clinical translation is hampered by inferior stability and short circulation time in the human body. Here, we report a general approach to manipulating the interaction between ONs and albumin by modulating hydrophobicity. A series of DNA aptamer derivatives were designed and prepared by programmable synthesis as an ON library with a gradient of hydrophobic base 'F'. In vitro experiments revealed that the introduction of two F bases at both ends of ONs enhanced the biostability without sacrificing biological activities, while the binding affinity toward albumin was dramatically increased with Kd in the range of 100 nM to 1 μM. In vivo imaging confirmed the immediate formation of the aptamer-albumin complex after the injection, and the circulation time of the aptamer was dramatically elongated owing to the enhanced biostability and retarded renal excretion. The programmable incorporation of the F base provides a general approach to regulating albumin-binding affinity and enhancing the stability of aptamers in vivo, conferring aptamer therapeutics prolonged circulation time to meet clinical requirements.
© The Author(s) 2022. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35293579      PMCID: PMC8989545          DOI: 10.1093/nar/gkac156

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  70 in total

1.  Albumin, a versatile carrier in oncology.

Authors:  F Kratz
Journal:  Int J Clin Pharmacol Ther       Date:  2010-07       Impact factor: 1.366

2.  Aptamers evolved from live cells as effective molecular probes for cancer study.

Authors:  Dihua Shangguan; Ying Li; Zhiwen Tang; Zehui Charles Cao; Hui William Chen; Prabodhika Mallikaratchy; Kwame Sefah; Chaoyong James Yang; Weihong Tan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-27       Impact factor: 11.205

Review 3.  Albumin-bound paclitaxel: a next-generation taxane.

Authors:  William J Gradishar
Journal:  Expert Opin Pharmacother       Date:  2006-06       Impact factor: 3.889

4.  Oligonucleotide drugs. A change of backbone.

Authors:  M Frank-Kamenetskii
Journal:  Nature       Date:  1991 Dec 19-26       Impact factor: 49.962

Review 5.  Recent progress in non-native nucleic acid modifications.

Authors:  Luke K McKenzie; Roberto El-Khoury; James D Thorpe; Masad J Damha; Marcel Hollenstein
Journal:  Chem Soc Rev       Date:  2021-04-26       Impact factor: 54.564

6.  Structural basis of the drug-binding specificity of human serum albumin.

Authors:  Jamie Ghuman; Patricia A Zunszain; Isabelle Petitpas; Ananyo A Bhattacharya; Masaki Otagiri; Stephen Curry
Journal:  J Mol Biol       Date:  2005-10-14       Impact factor: 5.469

7.  Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.

Authors:  M R Green; G M Manikhas; S Orlov; B Afanasyev; A M Makhson; P Bhar; M J Hawkins
Journal:  Ann Oncol       Date:  2006-06-01       Impact factor: 32.976

8.  Developing an Anticancer Copper(II) Multitarget Pro-Drug Based on the His146 Residue in the IB Subdomain of Modified Human Serum Albumin.

Authors:  Jun Wang; Yi Gou; Zhenlei Zhang; Ping Yu; Jinxu Qi; Qipin Qin; Hongbin Sun; Xiaoyang Wu; Hong Liang; Feng Yang
Journal:  Mol Pharm       Date:  2018-05-10       Impact factor: 4.939

9.  Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.

Authors:  S Agrawal; J Temsamani; J Y Tang
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

10.  Cell-specific aptamer probes for membrane protein elucidation in cancer cells.

Authors:  Dihua Shangguan; Zehui Cao; Ling Meng; Prabodhika Mallikaratchy; Kwame Sefah; Hui Wang; Ying Li; Weihong Tan
Journal:  J Proteome Res       Date:  2008-03-26       Impact factor: 4.466

View more
  1 in total

Review 1.  Recent advances in aptamer-based targeted drug delivery systems for cancer therapy.

Authors:  Fei Gao; Jianhui Yin; Yan Chen; Changyong Guo; Honggang Hu; Jiacan Su
Journal:  Front Bioeng Biotechnol       Date:  2022-08-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.